Asenapine and Mitapivat interaction
Asenapine and Mitapivat: the Asenapine prescribing label reports no clinically significant interaction between these two.
No clinically significant interaction reported. The label studied or considered this pair and found nothing meaningful.
What the FDA labels say
From the Asenapine (SAPHRIS) label · effective 2025-01-31
Drugs Having No Clinically Important Interactions with SAPHRIS No dosage adjustment of SAPHRIS is necessary when administered concomitantly with paroxetine (see Table 12 in Drug Interactions ( 7.1 ) for paroxetine dosage adjustment), imipramine, cimetidine, valproate, lithium, or a CYP3A4 inducer (e.g., carbamazepine, phenytoin, rifampin).
Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.
Open in the checkerNot medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.